ENTRADA THERAPEUTICS, INC. (TRDA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
12/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseTRDA / S&P -41.68% / 15.20% |
LoseTRDA / S&P -94.10% / 15.00% |
WinTRDA / S&P 114.05% / 50.40% |
| 2026-Q11/3 |
WinTRDA / S&P 22.76% / -4.33% |
LoseTRDA / S&P -96.67% / 11.30% |
LoseTRDA / S&P -639.19% / 27.70% |
| 2025-Q41/3 |
WinTRDA / S&P 77.24% / 2.65% |
LoseTRDA / S&P -87.94% / 9.00% |
LoseTRDA / S&P -288.04% / 13.40% |
| 2025-Q30/3 |
LoseTRDA / S&P -13.69% / 8.12% |
LoseTRDA / S&P -71.42% / 4.61% |
LoseTRDA / S&P -260.00% / 13.45% |
| 2025-Q20/3 |
LoseTRDA / S&P -25.66% / 10.94% |
LoseTRDA / S&P -66.80% / 4.83% |
LoseTRDA / S&P -162.29% / 10.63% |
| 2025-Q12/3 |
LoseTRDA / S&P -47.72% / -4.27% |
WinTRDA / S&P 5.74% / 4.98% |
WinTRDA / S&P 15.63% / 10.57% |
| 2024-Q42/3 |
WinTRDA / S&P 8.20% / 2.41% |
WinTRDA / S&P 63.38% / 5.25% |
LoseTRDA / S&P -836.00% / 6.15% |
| 2024-Q31/3 |
WinTRDA / S&P 12.14% / 5.89% |
LoseTRDA / S&P TRDA unavailable / 5.89% |
LoseTRDA / S&P -313.33% / 6.11% |
| 2024-Q20/3 |
LoseTRDA / S&P 0.56% / 4.28% |
LoseTRDA / S&P TRDA unavailable / 5.38% |
LoseTRDA / S&P -215.56% / 5.12% |
| 2024-Q10/3 |
LoseTRDA / S&P -6.10% / 10.56% |
LoseTRDA / S&P TRDA unavailable / 5.71% |
LoseTRDA / S&P -125.30% / 5.59% |
| 2023-Q40/3 |
LoseTRDA / S&P -4.49% / 11.69% |
LoseTRDA / S&P TRDA unavailable / 6.81% |
LoseTRDA / S&P -91.69% / 7.78% |
| 2023-Q31/3 |
WinTRDA / S&P 4.36% / -3.27% |
LoseTRDA / S&P TRDA unavailable / 7.52% |
LoseTRDA / S&P -105.44% / -5.03% |
| 2023-Q20/3 |
LoseTRDA / S&P 4.41% / 8.74% |
LoseTRDA / S&P TRDA unavailable / 9.50% |
LoseTRDA / S&P -153.43% / -8.57% |
| 2023-Q11/3 |
LoseTRDA / S&P 7.25% / 7.50% |
LoseTRDA / S&P TRDA unavailable / 10.77% |
WinTRDA / S&P 25.87% / -15.69% |
| 2022-Q40/3 |
LoseTRDA / S&P -14.21% / 7.56% |
LoseTRDA / S&P TRDA unavailable / 11.88% |
LoseTRDA / S&P -62.33% / -17.99% |
| 2022-Q31/3 |
WinTRDA / S&P 29.39% / -4.88% |
LoseTRDA / S&P TRDA unavailable / 13.47% |
LoseTRDA / S&P -143.83% / -1.41% |
| 2022-Q21/3 |
WinTRDA / S&P 29.71% / -16.10% |
LoseTRDA / S&P TRDA unavailable / 13.71% |
LoseTRDA / S&P -117.30% / 11.04% |
| 2022-Q10/3 |
LoseTRDA / S&P -45.15% / -4.60% |
LoseTRDA / S&P TRDA unavailable / 15.97% |
LoseTRDA / S&P TRDA unavailable / 42.23% |
| 2021-Q40/3 |
LoseTRDA / S&P TRDA unavailable / 11.03% |
LoseTRDA / S&P TRDA unavailable / 15.00% |
LoseTRDA / S&P TRDA unavailable / 96.40% |
| 2021-Q30/3 |
LoseTRDA / S&P TRDA unavailable / 0.58% |
LoseTRDA / S&P TRDA unavailable / 10.77% |
LoseTRDA / S&P TRDA unavailable / 69.42% |
| 2021-Q20/3 |
LoseTRDA / S&P TRDA unavailable / 8.55% |
LoseTRDA / S&P TRDA unavailable / 6.58% |
LoseTRDA / S&P TRDA unavailable / 51.81% |
| 2021-Q10/3 |
LoseTRDA / S&P TRDA unavailable / 6.17% |
LoseTRDA / S&P TRDA unavailable / -1.06% |
LoseTRDA / S&P TRDA unavailable / 7.39% |
| 2020-Q40/3 |
LoseTRDA / S&P TRDA unavailable / 12.15% |
LoseTRDA / S&P TRDA unavailable / -3.72% |
LoseTRDA / S&P TRDA unavailable / -33.42% |
| 2020-Q30/3 |
LoseTRDA / S&P TRDA unavailable / 8.93% |
LoseTRDA / S&P TRDA unavailable / -2.04% |
LoseTRDA / S&P TRDA unavailable / -27.10% |
| 2020-Q20/3 |
LoseTRDA / S&P TRDA unavailable / 20.54% |
LoseTRDA / S&P TRDA unavailable / -0.46% |
LoseTRDA / S&P TRDA unavailable / -27.11% |
| 2020-Q10/3 |
LoseTRDA / S&P TRDA unavailable / -19.60% |
LoseTRDA / S&P TRDA unavailable / 3.47% |
LoseTRDA / S&P TRDA unavailable / -14.75% |
| 2019-Q40/3 |
LoseTRDA / S&P TRDA unavailable / 9.07% |
LoseTRDA / S&P TRDA unavailable / 5.36% |
LoseTRDA / S&P TRDA unavailable / 2.99% |
| 2019-Q30/3 |
LoseTRDA / S&P TRDA unavailable / 1.70% |
LoseTRDA / S&P TRDA unavailable / 5.02% |
LoseTRDA / S&P TRDA unavailable / 0.21% |
| 2019-Q20/3 |
LoseTRDA / S&P TRDA unavailable / 4.30% |
LoseTRDA / S&P TRDA unavailable / 6.64% |
LoseTRDA / S&P TRDA unavailable / 8.65% |
| 2019-Q10/3 |
LoseTRDA / S&P TRDA unavailable / 13.65% |
LoseTRDA / S&P TRDA unavailable / 8.12% |
LoseTRDA / S&P TRDA unavailable / 14.29% |
| 2018-Q40/3 |
LoseTRDA / S&P TRDA unavailable / -13.52% |
LoseTRDA / S&P TRDA unavailable / 9.05% |
LoseTRDA / S&P TRDA unavailable / 18.23% |
| 2018-Q30/3 |
LoseTRDA / S&P TRDA unavailable / 7.71% |
LoseTRDA / S&P TRDA unavailable / 10.21% |
LoseTRDA / S&P TRDA unavailable / 19.06% |
| 2018-Q20/3 |
LoseTRDA / S&P TRDA unavailable / 3.43% |
LoseTRDA / S&P TRDA unavailable / 9.03% |
LoseTRDA / S&P TRDA unavailable / 14.46% |
| 2018-Q10/3 |
LoseTRDA / S&P TRDA unavailable / -0.76% |
LoseTRDA / S&P TRDA unavailable / 7.68% |
LoseTRDA / S&P TRDA unavailable / 12.46% |
| 2017-Q40/3 |
LoseTRDA / S&P TRDA unavailable / 6.64% |
LoseTRDA / S&P TRDA unavailable / 7.03% |
LoseTRDA / S&P TRDA unavailable / 13.82% |
| 2017-Q30/3 |
LoseTRDA / S&P TRDA unavailable / 4.48% |
LoseTRDA / S&P TRDA unavailable / 5.68% |
LoseTRDA / S&P TRDA unavailable / 17.57% |
| 2017-Q20/3 |
LoseTRDA / S&P TRDA unavailable / 3.09% |
LoseTRDA / S&P TRDA unavailable / 4.83% |
LoseTRDA / S&P TRDA unavailable / 17.74% |
| 2017-Q10/3 |
LoseTRDA / S&P TRDA unavailable / 6.07% |
LoseTRDA / S&P TRDA unavailable / 3.67% |
LoseTRDA / S&P TRDA unavailable / 13.32% |
| 2016-Q40/3 |
LoseTRDA / S&P TRDA unavailable / 3.82% |
LoseTRDA / S&P TRDA unavailable / 2.09% |
LoseTRDA / S&P TRDA unavailable / 7.05% |
| 2016-Q30/3 |
LoseTRDA / S&P TRDA unavailable / 3.85% |
LoseTRDA / S&P TRDA unavailable / 0.20% |
LoseTRDA / S&P TRDA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | TRDA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 32.91% | 20.78% |
| Annualized return | 32.91% | 20.78% |
5Y · 2021-10-29 to 2026-08-27
| Metric | TRDA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -69.65% | 83.14% |
| Annualized return | -21.21% | 12.86% |
10Y · 2021-10-29 to 2026-08-27
| Metric | TRDA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -69.65% | 319.30% |
| Annualized return | -11.24% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |